This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
New eMC coming June 2013...

Actavis UK Ltd

Whiddon Valley, Barnstaple, Devon, EX32 8NS, UK
Telephone: +44 (0)1271 311 200
Fax: +44 (0)1271 346 106
WWW: http://www.actavis.co.uk
Medical Information Direct Line: +44 (0)1271 311 257
Medical Information e-mail: medinfo@actavis.co.uk

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 04/07/2012
SPC Vitamin B Compound Strong Tablets


Go to top of the page
1. Name of the medicinal product

VITAMIN B COMPOUND STRONG TABLETS


Go to top of the page
2. Qualitative and quantitative composition

Each tablet contains 20mg Nicotinamide, 2mg Pyridoxine Hydrochloride, 2mg Riboflavine, 4.85mg Thiamine Mononitrate .

Also contains lactose.

For a full list of excipients, see section 6.1


Go to top of the page
3. Pharmaceutical form

Film-coated tablet.

Brown, circular, biconvex film-coated tablets with the identifying letters “VB” embossed on one side.


Go to top of the page
4. Clinical particulars

Go to top of the page
4.1 Therapeutic indications

1) For the treatment of clinical and sub-clinical vitamin B deficiency states (manifestations of which include glossitis, stomatitis, cheilosis, the heart manifestations of beriberi, the skin manifestations of pellagra, corneal vascularisation and polyneuritis).


Go to top of the page
4.2 Posology and method of administration

Adults (including elderly) and children over 3 years: One to two tablets three times daily.

Children under 3 years: Not recommended.

For oral administration.


Go to top of the page
4.3 Contraindications

Known hypersensitivity to any of the active constituents.


Go to top of the page
4.4 Special warnings and precautions for use

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Pyridoxine may increase the peripheral metabolism of levodopa, reducing therapeutic efficacy of the latter drug. Therefore, patients with Parkinson's disease who are receiving treatment with plain levodopa should not take vitamin B6 in doses which greatly exceed the daily requirement. This does not apply when levodopa is combined with a peripheral decarboxylase inhibitor.


Go to top of the page
4.6 Pregnancy and lactation

The usual precautions should be observed when administering drugs during pregnancy, especially in the first trimester.

In high doses, pyridoxine may interfere with prolactin release and should only be used with caution in nursing mothers.


Go to top of the page
4.7 Effects on ability to drive and use machines

None known.


Go to top of the page
4.8 Undesirable effects

Toxic effects are unlikely since any excess vitamin B is excreted.


Go to top of the page
4.9 Overdose

Excess vitamin B is readily excreted, therefore no serious problems are anticipated for the administration of vitamin B in this form.


Go to top of the page
5. Pharmacological properties

Go to top of the page
5.1 Pharmacodynamic properties

Nicotinamide is a vitamin

Pyridoxine hydrochloride is a vitamin (B6)

Riboflavine is a vitamin (B2)

Thiamine mononitrate is a vitamin (B1)

The vitamin B-complex comprises a group of water-soluble factors more or less closely associated in their natural occurrence. It is known that nearly every vitamin of the B-complex forms part of a co-enzyme essential for the metabolism of protein, carbohydrate or fatty acid.


Go to top of the page
5.2 Pharmacokinetic properties

Nicotinamide is readily absorbed from the GI tract following oral administration and is widely distributed in the body tissues. Small amounts of nicotinamide are excreted unchanged in urine following therapeutic doses, however, the amount excreted unchanged is increased with larger doses.

Pyridoxine is absorbed from the GI tract and is converted to the active form pyridoxal phosphate. It is excreted in the urine as 4-pyridoxic acid.

Riboflavine is absorbed from the GI tract and in the circulation is bound to plasma proteins. Although widely distributed, little is stored in the body, and amounts in excess of requirements are excreted in the urine.

Thiamine is absorbed from the GI tract and is widely distributed to most body tissues. It is not stored to any appreciable extent in the body and amounts in excess of requirements are excreted in the urine as unchanged thiamine or metabolites.


Go to top of the page
5.3 Preclinical safety data

Not applicable.


Go to top of the page
6. Pharmaceutical particulars

Go to top of the page
6.1 List of excipients

Tablet core contains:

Lactose monohydrate

Magnesium stearate

Maize starch

Pregelatinised maize starch

Stearic acid

Film-coat contains:

Hypromellose

Hydroxypropyl Cellulose

Medium Chain Triglycerides

Macrogol 3350

Titanium Dioxide (E171)

Iron oxide Red (E172)

Iron oxide Black (E172)


Go to top of the page
6.2 Incompatibilities

None known.


Go to top of the page
6.3 Shelf life

Shelf-life

Three years from the date of manufacture.

Shelf-life after dilution/reconstitution

Not applicable.

Shelf-life after first opening

Not applicable.


Go to top of the page
6.4 Special precautions for storage

Store below 25°C in a dry place.


Go to top of the page
6.5 Nature and contents of container

The product containers are rigid injection moulded polypropylene or injection blow-moulded polyethylene tablet containers with polyfoam wad or polyethylene ullage filler and snap-on polyethylene lids; in case any supply difficulties should arise the alternative is amber glass bottles with screw caps and polyfoam wad or cotton wool.

The product may also be supplied in blister packs in cartons:

a) Carton: Printed carton manufactured from white folding box board.

b) Blister pack: (i) 250µm white rigid PVC. (ii) Surface printed 20µm hard temper aluminium foil with 5-7g/M² PVC and PVdC compatible heat seal lacquer on the reverse side.

Pack sizes: 28, 30, 56, 60, 84, 90, 100, 112, 120, 168, 180, 250, 500, 1000.

Product may also be supplied in bulk packs, for reassembly purposes only, in polybags contained in tins, skillets or polybuckets filled with suitable cushioning material. Bulk packs are included for temporary storage of the finished product before final packaging into the proposed marketing containers.

Maximum size of bulk packs: 50,000.


Go to top of the page
6.6 Special precautions for disposal and other handling

Not applicable.


Go to top of the page
Administrative data

Go to top of the page
7. Marketing authorisation holder

Name or style and permanent address of registered place of business of the holder of the Marketing Authorisation:

Actavis UK Limited

(Trading style: Actavis)

Whiddon Valley

BARNSTAPLE

N Devon EX32 8NS


Go to top of the page
8. Marketing authorisation number(s)

PL 0142/5538 R


Go to top of the page
9. Date of first authorisation/renewal of the authorisation

Granted: 19.9.86

(Product Licence of Right: 31.5.73)

(Renewed: 23.12.91, 26.4.99)


Go to top of the page
10. Date of revision of the text

06/11/2009



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/24104/SPC/


Active Ingredients/Generics